S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Log in

Cardiff Oncology Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
-0.46 (-3.97 %)
(As of 01/20/2021 12:00 AM ET)
Today's Range
Now: $11.14
50-Day Range
MA: $16.75
52-Week Range
Now: $11.14
Volume7.10 million shs
Average Volume648,892 shs
Market Capitalization$122.66 million
P/E RatioN/A
Dividend YieldN/A
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Cardiff Oncology logo


Overall MarketRank

0.58 out of 5 stars

Medical Sector

1337th out of 1,928 stocks

Biological Products, Except Diagnostic Industry

153rd out of 177 stocks

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:TROV
Phone(858) 952-7570



Sales & Book Value

Annual Sales$250,000.00
Book Value$0.94 per share


Net Income$-16,410,000.00
Net Margins-3,688.31%


Market Cap$122.66 million
Next Earnings DateN/A

Receive TROV News and Ratings via Email

Sign-up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Cardiff Oncology (NASDAQ:TROV) Frequently Asked Questions

Is Cardiff Oncology a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cardiff Oncology stock.
View analyst ratings for Cardiff Oncology
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Cardiff Oncology?

Wall Street analysts have given Cardiff Oncology a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cardiff Oncology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Cardiff Oncology's CEO?

1,428 employees have rated Cardiff Oncology CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Cardiff Oncology's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:TROV) posted its quarterly earnings results on Thursday, February, 27th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.14. The medical research company earned $0.09 million during the quarter. Cardiff Oncology had a negative net margin of 3,688.31% and a negative return on equity of 202.00%.
View Cardiff Oncology's earnings history

When did Cardiff Oncology's stock split? How did Cardiff Oncology's stock split work?

Shares of Cardiff Oncology reverse split on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 19th 2019. An investor that had 100 shares of Cardiff Oncology stock prior to the reverse split would have 17 shares after the split.

Who are some of Cardiff Oncology's key competitors?

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include XOMA (XOMA), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), NVIDIA (NVDA), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY), Alibaba Group (BABA), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN) and Idera Pharmaceuticals (IDRA).

Who are Cardiff Oncology's key executives?

Cardiff Oncology's management team includes the following people:
  • Mark Erlander, Chief Executive Officer & Director
  • Vicki Kelemen, Chief Operating Officer & Executive Vice President
  • Brigitte Lindsay, Secretary & Vice President-Finance

What is Cardiff Oncology's stock symbol?

Cardiff Oncology trades on the NASDAQ under the ticker symbol "TROV."

What is Cardiff Oncology's stock price today?

One share of TROV stock can currently be purchased for approximately $11.14.

How big of a company is Cardiff Oncology?

Cardiff Oncology has a market capitalization of $122.66 million and generates $250,000.00 in revenue each year. The medical research company earns $-16,410,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis.

What is Cardiff Oncology's official website?

The official website for Cardiff Oncology is www.trovagene.com.

How can I contact Cardiff Oncology?

Cardiff Oncology's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company can be reached via phone at (858) 952-7570 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.